Tibenelast sodium (LY 186655) is primarily researched for its potential therapeutic applications in inflammatory and respiratory conditions. It acts as a leukotriene inhibitor, targeting pathways involved in inflammation, making it a candidate for treating asthma and other bronchial disorders. Its mechanism of action helps reduce airway inflammation and hyperresponsiveness, potentially improving lung function in patients. Additionally, studies explore its use in managing chronic obstructive pulmonary disease (COPD) and other inflammatory diseases where leukotrienes play a significant role. Research continues to evaluate its efficacy and safety in clinical settings.